149 related articles for article (PubMed ID: 102417)
1. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
3. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
4. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine as a single second-line agent in ovarian cancer.
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
[TBL] [Abstract][Full Text] [Related]
7. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
8. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine in advanced head and neck cancer. A phase II study.
Gad-El-Mawla N; Macdonald JS; Khaled H
Am J Clin Oncol; 1984 Jun; 7(3):205-8. PubMed ID: 6428214
[TBL] [Abstract][Full Text] [Related]
10. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Wharton JT; Rutledge F; Smith JP; Herson J; Hodge MP
Am J Obstet Gynecol; 1979 Apr; 133(7):833-44. PubMed ID: 219695
[TBL] [Abstract][Full Text] [Related]
11. Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma.
Omura GA; Greco FA; Birch R
Cancer Treat Rep; 1981; 65(5-6):530-1. PubMed ID: 6786741
[No Abstract] [Full Text] [Related]
12. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
Weiss RB
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
[No Abstract] [Full Text] [Related]
13. Hexamethylmelamine in adenocarcinoma of the pancreas and liver.
Oldham DS; Wampler GL
Med Pediatr Oncol; 1983; 11(4):297-8. PubMed ID: 6310359
[TBL] [Abstract][Full Text] [Related]
14. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
Vergote I; Himmelmann A; Frankendal B; Scheistrøen M; Vlachos K; Tropé C
Gynecol Oncol; 1992 Dec; 47(3):282-6. PubMed ID: 1473738
[TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Gershanovich ML; Livshits ME; Antipenkova VI
Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
[TBL] [Abstract][Full Text] [Related]
16. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
17. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
18. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Lund B; Aabo K; Rørth M; Hansen HH
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
[TBL] [Abstract][Full Text] [Related]
19. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Keldsen N; Havsteen H; Vergote I; Bertelsen K; Jakobsen A
Gynecol Oncol; 2003 Feb; 88(2):118-22. PubMed ID: 12586589
[TBL] [Abstract][Full Text] [Related]
20. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Rosen GF; Lurain JR; Newton M
Gynecol Oncol; 1987 Jun; 27(2):173-9. PubMed ID: 3106174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
